Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_assertion type Assertion NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_head.
- NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_assertion description "[An everyday clinical practice dilemma in the 20-30% of metastatic colorectal cancer (CRC) patients that have not been operated on their primary tumour, is, under which specific histopathology and molecular circumstances, an endoscopic biopsy could be considered adequate to provide a representative RAS/BRAF molecular status to guide treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_provenance.
- NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_assertion evidence source_evidence_literature NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_provenance.
- NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_assertion SIO_000772 26325103 NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_provenance.
- NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_assertion wasDerivedFrom befree-2016 NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_provenance.
- NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_assertion wasGeneratedBy ECO_0000203 NP1293498.RAHELIYQLPKL-CM0m87h0IdUeBp5yPM9bcnfsccVVMlSY130_provenance.